What are the indications, recommended dosing regimen, monitoring requirements, and contraindications for Olaparib in adult patients with confirmed germline or somatic BRCA1/2 mutations (or other homologous recombination repair deficiency) who have ovarian, breast, pancreatic, or prostate cancer?

Olaparib: Indications, Dosing, Monitoring, and Contraindications

Olaparib is indicated for maintenance therapy in patients with germline or somatic BRCA1/2 mutations across multiple cancer types, with specific dosing of 300 mg twice daily (tablet formulation) or 400 mg twice daily (capsule formulation), requiring baseline and periodic monitoring for hematologic toxicity.

Approved Indications by Cancer Type

Ovarian/Fallopian Tube/Primary Peritoneal Cancer

First-Line Maintenance (Category 1):

• Patients with germline or somatic BRCA1/2 mutations who achieved complete or partial response to first-line platinum-based chemotherapy 1
• Can be used as monotherapy OR in combination with bevacizumab in patients with HRD-positive tumors 1
• The SOLO-1 trial demonstrated 67% of patients alive at 7 years with olaparib vs 46% with placebo 1

Second-Line Maintenance (Category 1):

• Limited to patients with germline or somatic BRCA mutations who are PARP inhibitor-naïve 1
• FDA restricted second-line maintenance to BRCA-mutated cancers only following safety concerns 1
• Category 2A if disease did not progress during prior PARP inhibitor treatment 1

Recurrent Disease Treatment:

• FDA approved in 2014 for patients with advanced ovarian cancer after ≥3 lines of chemotherapy with germline BRCA mutation 1
• Response rates of 31.1% in heavily pretreated BRCA-mutated ovarian cancer 2, 3

Breast Cancer

Adjuvant Setting:

• Addition of 1 year of adjuvant olaparib after completion of adjuvant chemotherapy in select patients with germline BRCA1/2 mutation 4
• Listed as a preferred regimen for patients with germline BRCA1/2 mutations 4

Metastatic Setting:

• Response rate of 12.9% in heavily pretreated breast cancer (≥3 prior chemotherapy regimens) with germline BRCA1/2 mutations 2

Pancreatic Cancer

• Indicated after prior gemcitabine treatment in patients with germline BRCA1/2 mutations 2
• Response rate of 21.7% observed in phase II studies 2

Prostate Cancer

• Indicated after progression on hormonal therapy and one systemic therapy in patients with germline BRCA1/2 mutations 2
• Response rate of 50% in small cohort (n=8) 2

Dosing Regimen

Standard Dosing:

• Tablet formulation: 300 mg orally twice daily (preferred current formulation)
• Capsule formulation: 400 mg orally twice daily (older formulation used in trials) 1, 3

Duration:

• First-line ovarian cancer maintenance: 2 years or until disease progression 1
• Adjuvant breast cancer: 1 year 4
• Recurrent disease: Continue until progression or unacceptable toxicity

Dose Modifications:

• Reduced dosing (150 mg twice daily) may be considered in very elderly or frail patients with significant comorbidities 5
• Dose reduction to manage toxicity occurred in approximately 21% of patients in real-world data 6

Monitoring Requirements

Baseline Assessment:

• Complete blood count (CBC) with differential
• Renal function (creatinine clearance)
• Confirm germline or somatic BRCA1/2 mutation status through validated testing 1
• Consider HRD testing if combination with bevacizumab is planned 1

Ongoing Monitoring:

• Hematologic: CBC monthly or more frequently if abnormalities develop
  • Anemia is the most common Grade 3-4 toxicity (17% of patients) 2
  • Thrombocytopenia and neutropenia also occur 1
• Clinical assessment: Fatigue, nausea, vomiting (most common adverse events) 2
• Imaging: Per standard of care for disease monitoring

Critical Safety Consideration:

• Long-term safety data raised concerns about overall survival in platinum-resistant disease when used as active treatment (not maintenance) 1
• Monitor for therapy-induced clonal hematopoiesis with prolonged use 7

Contraindications and Precautions

Absolute Contraindications:

• Hypersensitivity to olaparib or any component

Relative Contraindications/Cautions:

• Platinum-resistant disease: Use as active treatment (not maintenance) associated with worse overall survival in ARIEL-4 trial 1
• Prior PARP inhibitor progression: Limited data support repeat PARP inhibitor use 1
• Severe renal impairment: Dose adjustment required; use with caution 5
• Baseline cytopenias: May require dose modification or delay

Important Restrictions:

• Do NOT use bevacizumab + PARP inhibitor combination in recurrent disease setting (not recommended by NCCN panel) 1
• HRD-negative tumors: Olaparib + bevacizumab showed no benefit in HRD-negative ovarian cancer 1
• Colorectal cancer with ATM mutations: No effectiveness observed 8

Patient Selection Considerations

Best Candidates:

• BRCA1/2 mutation carriers (germline or somatic) with platinum-sensitive disease
• Patients achieving complete or partial response to platinum-based chemotherapy
• PARP inhibitor-naïve patients (strongest evidence)
• Normal or near-normal CA-125 at baseline correlates with longer PFS 6

Uncertain Benefit:

• Non-BRCA HRR gene mutations show heterogeneous responses 7
• Specific benefit seen in BAP1, BARD1, BRIP1, and PALB2 mutations 9
• CDK12 and RAD51B alterations may respond 8
• No responses in ARID1A, ATR, ATRX, PPP2R2A, CHEK1 alterations 9, 8

Common Pitfall: Do not assume all HRD mutations predict PARP inhibitor sensitivity—BRCA1/2 mutations have the strongest evidence, and non-BRCA HRR alterations require individualized assessment based on specific gene involved 7.